Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chemotherapy for chronic leukemia]

K Kitajima, I Takahashi, S Fujimoto

    Gan to Kagaku Ryoho. Cancer & Chemotherapy
    |November 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Chemotherapy for chronic myelogenous leukemia (CML) shows promise in blastic phase with combination therapies, achieving remissions in over a third of patients. Chronic phase treatments like the L-15 protocol offer temporary benefits but require further development for sustained remission.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Apoptosis of peripheral leukocytes in patients with myelodysplastic syndromes].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·1998
    Same author

    Coexistence of Pemphigus vulgaris and herpes simplex virus infection in oral mucosa diagnosed by cytology, immunohistochemistry, and polymerase chain reaction.

    Diagnostic cytopathology·1998
    Same author

    [Hemophilia A with inhibitor].

    Ryoikibetsu shokogun shirizu·1998
    Same author

    [Hemophilia B with inhibitor].

    Ryoikibetsu shokogun shirizu·1998
    Same author

    [Acquired inhibitor to coagulation factor V].

    Ryoikibetsu shokogun shirizu·1998
    Same author

    Treatment of advanced gastric cancer with 5-fluorouracil and cisplatin in combination with dipyridamole.

    International journal of oncology·1998
    Same journal

    [A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Recent Advances in the Treatment of HER2-Altered Solid Tumors].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [BRAF-Mutant Solid Tumor].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Pharmacology

    Context:

    • Chronic Myelogenous Leukemia (CML) presents distinct challenges in its chronic and blastic phases.
    • Advances in chemotherapy aim to improve outcomes for CML patients across different disease stages.
    • Current treatment strategies involve multi-agent protocols and targeted therapies.

    Purpose:

    • To review and summarize current chemotherapy approaches for chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL).
    • To highlight recent advancements in treating the blastic phase of CML.
    • To discuss the efficacy and limitations of specific chemotherapy regimens.

    Summary:

    • The L-15 protocol, an intensive chemotherapy for CML chronic phase, induced Ph1-negative cell repopulation in about half of patients, though remissions were often short-lived.

    Related Experiment Videos

  • Significant progress has been made in blastic phase CML chemotherapy, with vincristine and prednisolone combinations achieving complete remission in over one-third of patients.
  • For chronic lymphocytic leukemia (CLL) at Rai stage III, initial chemotherapy recommendations include chlorambucil, cyclophosphamide, or corticosteroids.

    • Impact:

    • Improved survival rates for CML blastic crisis patients are being observed with current combination chemotherapy regimens.
    • The findings underscore the need for more durable treatment strategies for CML in its chronic phase.
    • This review provides a concise overview of chemotherapy options for specific leukemic conditions, aiding clinical decision-making.